The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastomaMin Pan, Paul Geeleher, William C. Wright et al.|Nature Communications|2021Cited by 95
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinomaAllison M. Kirk, Paul G. Thomas, Ravi K. Shah et al.|Cell Reports Medicine|2024Cited by 15
The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastomaMin Pan, Paul Geeleher, William C. Wright et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 6